BioCardia (NASDAQ:BCDA) Rating Increased to Sell at Wall Street Zen

BioCardia (NASDAQ:BCDA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of BioCardia in a research note on Tuesday, June 9th. Zacks Research cut shares of BioCardia from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, BioCardia currently has an average rating of “Reduce” and a consensus price target of $25.00.

BioCardia Stock Performance

Shares of BCDA opened at $0.83 on Friday. The firm has a market capitalization of $9.40 million, a price-to-earnings ratio of -0.91 and a beta of 0.44. BioCardia has a one year low of $0.78 and a one year high of $2.42. The stock’s fifty day moving average is $0.97 and its 200-day moving average is $1.14.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Analysts forecast that BioCardia will post -0.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioCardia news, Director Simon H. Stertzer acquired 39,000 shares of BioCardia stock in a transaction dated Tuesday, June 23rd. The stock was bought at an average price of $1.00 per share, for a total transaction of $39,000.00. Following the transaction, the director owned 166,338 shares in the company, valued at approximately $166,338. This trade represents a 30.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have bought 146,900 shares of company stock valued at $140,092. 17.40% of the stock is currently owned by corporate insiders.

Institutional Trading of BioCardia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers bought a new stake in BioCardia during the second quarter worth approximately $40,000. Geode Capital Management LLC increased its holdings in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after buying an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC bought a new position in shares of BioCardia in the fourth quarter valued at $72,000. 20.57% of the stock is currently owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.